Abstract
Summary
The global PCR-based infectious diseases market is expected to reach USD 7,720,895.13 thousand by 2031 from USD 4,737,570.00 thousand in 2023, growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.
Market Segmentation
Global PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) – Industry Trends and Forecast to 2031
Overview of Global PCR-based Infectious Diseases Market Dynamics
Driver
• Increasing PCR-based research activities
Restraint
• High cost of PCR test services
Opportunity
• Disease surveillance for early detection and monitoring of infectious diseases
Market Players
Some of the major market players operating in the global PCR-based infectious diseases market are:
• DNA Labs India
• DrSafeHands
• Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
• Max Lab
• MicroGen Diagnostics
• pathlab
• The Washington Travel Clinic
• Clarewell Clinics
• AZOVA
• One Life Home Health Care Center
• LalpathLabs
Table of Contents
1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 45
1.4 CURRENCY AND PRICING 46
1.5 LIMITATIONS 47
1.6 MARKETS COVERED 47
2 MARKET SEGMENTATION 50
2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.6 MULTIVARIATE MODELLING 57
2.7 MARKET APPLICATION COVERAGE GRID 58
2.8 TEST TYPE LIFELINE CURVE 59
2.9 DBMR MARKET POSITION GRID 60
2.10 VENDOR SHARE ANALYSIS 61
2.11 SECONDARY SOURCES 62
2.12 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 69
4.2 PORTER’S FIVE FORCES 70
5 MARKET OVERVIEW 71
5.1 DRIVERS 73
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 73
5.1.2 RISING CASES OF INFECTIOUS DISEASES 73
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 74
5.2 RESTRAINTS 75
5.2.1 HIGH COST OF PCR TEST SERVICES 75
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 76
5.3 OPPORTUNITIES 77
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 77
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 77
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 78
5.4 CHALLENGES 79
5.4.1 DATA SECURITY AND PRIVACY CONCERNS 79
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 79
6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 81
6.1 OVERVIEW 82
6.2 TUBERCULOSIS PCR TEST 88
6.3 HEPATITIS PCR TEST 88
6.3.1 HEPATITIS C PCR TEST 89
6.3.2 HEPATITIS B PCR TEST 89
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 90
6.5 INFLUENZA PCR TEST 90
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 91
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 91
6.8 GONORRHEA PCR TEST 92
6.9 SALMONELLOSIS PCR TEST 92
6.10 ROTAVIRUS PCR TEST 93
6.11 BORDETELLA PCR TEST 93
6.12 H. PYLORI PCR TEST 94
6.13 SARS (COVID-19) PCR TEST 94
6.14 NOROVIRUS PCR TEST 95
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 95
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 96
6.17 ENTEROCOCCUS PCR TEST 96
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 97
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 97
6.20 OTHERS PCR TEST 98
7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 99
7.1 OVERVIEW 100
7.2 VIRAL INFECTION 103
7.2.1 SARS (COVID-19) INFECTION 103
7.2.2 ROTAVIRUS INFECTION 103
7.2.3 NOROVIRUS INFECTION 103
7.2.4 OTHERS 104
7.3 RESPIRATORY TRACT INFECTION 104
7.3.1 INFLUENZA 104
7.3.2 TUBERCULOSIS 104
7.3.3 BORDETELLA 105
7.4 SEXUALLY TRANSMITTED INFECTION 105
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 106
7.4.2 GONORRHEA 106
7.4.3 HEAPTITIS 106
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 106
7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 106
7.4.6 MYCOPLASMA GENITALIUM (MG) 106
7.4.7 OTHERS 106
7.5 HOSPITAL ACQUIRED INFECTIONS 107
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 107
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 107
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 108
7.5.4 OTHERS 108
7.6 OTHER INFECTIONS 108
7.6.1 SALMONELLOSIS 108
7.6.2 H. PYLORI 109
7.6.3 ENTEROCOCCUS INFECTIONS 109
7.6.4 OTHERS 109
8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 110
8.1 OVERVIEW 111
8.2 VIRAL 114
8.3 BACTERIAL 114
8.4 FUNGAL 115
8.5 PROTOZOA 115
8.6 OTHERS 116
9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 117
9.1 OVERVIEW 118
9.2 RT PCR 121
9.3 MULTIPLEX PCR 121
9.4 OTHERS 122
10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 123
10.1 OVERVIEW 124
10.2 GERIATRIC 127
10.3 PEDIATRIC 127
10.4 ADULTS 128
11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 129
11.1 OVERVIEW 130
11.2 LABORATORY BASED TESTING 133
11.3 POINT OF CARE TESTING 133
12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 134
12.1 OVERVIEW 135
12.2 DIAGNOSTIC CENTERS 138
12.3 HOSPITAL 138
12.4 CLINICS 139
12.5 COMMUNITY HEALTH CENTERS 139
12.6 ACADEMIC AND RESEARCH INSTITUTES 140
12.7 HOME HEALTHCARE 140
12.8 OTHERS 141
13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 142
13.1 OVERVIEW 143
13.2 NORTH AMERICA 147
13.2.1 U.S 156
13.2.2 CANADA 164
13.2.3 MEXICO 172
13.3 EUROPE 180
13.3.1 GERMANY 189
13.3.2 FRANCE 197
13.3.3 U.K 205
13.3.4 ITALY 213
13.3.5 RUSSIA 221
13.3.6 SPAIN 229
13.3.7 TURKEY 237
13.3.8 NETHERLANDS 245
13.3.9 SWITZERLAND 253
13.3.10 BELGIUM 261
13.3.11 HUNGARY 269
13.3.12 REST OF EUROPE 277
13.4 ASIA PACIFIC 280
13.4.1 CHINA 290
13.4.2 AUSTRALIA 298
13.4.3 JAPAN 306
13.4.4 INDIA 314
13.4.5 SOUTH KOREA 322
13.4.6 SINGAPORE 330
13.4.7 MALAYISA 338
13.4.8 THAILAND 346
13.4.9 INDONESIA 354
13.4.10 PHILIPPINES 362
13.4.11 REST OF ASIA-PACIFIC 370
13.5 SOUTH AMERICA 373
13.5.1 BRAZIL 382
13.5.2 ARGENTINA 390
13.5.3 REST OF SOUTH AMERICA 398
13.6 MIDDLE EAST AND AFRICA 401
13.6.1 SOUTH AFRICA 410
13.6.2 U.A.E 418
13.6.3 SAUDI ARABIA 426
13.6.4 EGYPT 434
13.6.5 ISRAEL 442
13.6.6 REST OF MIDDLE EAST AND AFRICA 450
14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 453
14.1 COMPANY SHARE ANALYSIS: GLOBAL 453
15 SWOT ANALYSIS 454
16 COMPANY PROFILE 455
16.1 MICROGEN DIAGNOSTICS 455
16.1.1 COMPANY SNAPSHOT 455
16.1.2 SERVICE PORTFOLIO 455
16.1.3 RECENT DEVELOPMENTS 456
16.2 MAX LAB 457
16.2.1 COMPANY SNAPSHOT 457
16.2.2 SERVICE PORTFOLIO 457
16.3 DNA LABS INDIA 459
16.3.1 COMPANY SNAPSHOT 459
16.3.2 SERVICE PORTFOLIO 459
16.3.3 RECENT DEVELOPMENT 460
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD 461
16.4.1 COMPANY SNAPSHOT 461
16.4.2 SERVICE PORTFOLIO 461
16.4.3 RECENT DEVELOPMENT 462
16.5 LALPATHLABS 463
16.5.1 COMPANY SNAPSHOT 463
16.5.2 REVENUE ANALYSIS 463
16.5.3 PRODUCT PORTFOLIO 464
16.5.4 RECENT DEVELOPMENTS 464
16.6 AZOVA 465
16.6.1 COMPANY SNAPSHOT 465
16.6.2 PRODUCT PORTFOLIO 465
16.6.3 RECENT DEVELOPMENTS 465
16.7 CLAREWELL CLINICS 466
16.7.1 COMPANY SNAPSHOT 466
16.7.2 PRODUCT DESCRIPTION 466
16.7.3 RECENT DEVELOPMENTS 466
16.8 DRSAFEHANDS 467
16.8.1 COMPANY SNAPSHOT 467
16.8.2 SERVICE PORTFOLIO 467
16.8.3 RECENT DEVELOPMENT 467
16.9 ONE LIFE HOME HEALTH CARE CENTER 468
16.9.1 COMPANY SNAPSHOT 468
16.9.2 PRODUCT DESCRIPTION 468
16.9.3 RECENT DEVELOPMENTS 468
16.10 PATHLAB 469
16.10.1 COMPANY SNAPSHOT 469
16.10.2 SERVICE PORTFOLIO 469
16.10.3 RECENT DEVELOPMENT 469
16.11 THE WASHINGTON TRAVEL CLINIC 470
16.11.1 COMPANY SNAPSHOT 470
16.11.2 SERVICE PORTFOLIO 470
16.11.3 RECENT DEVELOPMENT 471
17 QUESTIONNAIRE 472
18 RELATED REPORTS 476